Many glaucoma patients struggle daily to get their eyedrops in properly, DURYSTA™ was designed to offer patients an alternative IOP lowering option to topical eyedrops.


In June 2020, DURYSTA™ became the first intracamedral, biodegradeable sustained-release implant indicated to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). It is a small plug of the most common class of glaucoma medication that is placed painlessly into the eye in less than a minute. It is preservative-free and slowly biodegrades over time, lasting 6-12 months in most patients.

DURYSTA™ allows both physicians and patients the confidence that IOP is consistently controlled every day, reducing the risk of blindmess. It is contraindicated in patients with Fuch’s Dystrophy, history of corneal transplant, aphakia, or hypersensitivity to bimatoptost. If eyedrops are a challenge for you or your loved one, please visit us to see if DURYSTA™ can help.

Get In Touch With Us
Have Questions? Feel free to contact us and our team will get back to you as soon as possible.